Sinovac Biotech Equity 2024

Sinovac Biotech Aktienanalyse

What does Sinovac Biotech do?

Sinovac Biotech Ltd is a Chinese biopharmaceutical company specializing in researching, developing, manufacturing, and marketing vaccines for infectious diseases. The company was founded in 2001 and is headquartered in Beijing. The history of Sinovac began with the establishment of the company by CEO Dr. Yin Weidong. Dr. Yin was an experienced researcher in the field of vaccine development and had previously worked at the China Academy of Medical Sciences. His vision was to establish a company that produces innovative vaccines against severe and potentially life-threatening diseases. Sinovac's business model is based on the discovery and development of vaccines against viral diseases. The company works closely with leading research and development institutes in China to develop its products. It has several production facilities in China that meet the highest international standards and ensure excellent quality assurance. Sinovac specializes in various areas, including influenza, hepatitis, pneumococcal, rotavirus, rubella, and SARS vaccines. It is the only company in China authorized to manufacture and sell the inactivated seasonal flu vaccine used in China every year. Furthermore, Sinovac has successfully developed an inactivated hepatitis A vaccine and an inactivated Sinovac RS vaccine, which uses a unique technology to protect the vaccine against rejection reactions and adverse side effects. One of Sinovac's most significant products is the Sinovac CoronaVac vaccine, which is being used worldwide under emergency authorization by the World Health Organization to combat the Covid-19 pandemic. The vaccine has been successfully deployed in many countries worldwide and has shown high effectiveness against the virus. Sinovac also has a long history of collaborating with international organizations and governments to provide vaccines for the prevention of infectious diseases. It is an important supplier of vaccines to the Chinese government and has successfully developed vaccines against the swine flu epidemic and enterovirus, which are widespread in China. Overall, Sinovac is strongly committed to research, development, and manufacturing innovation. The company has taken a leadership role in combating infectious diseases in China and globally, and has an impressive track record in the development and production of vaccines at the highest level. Sinovac Biotech ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Sinovac Biotech's Equity

Sinovac Biotech's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Sinovac Biotech's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Sinovac Biotech's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Sinovac Biotech's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Sinovac Biotech’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Sinovac Biotech stock

What is the equity of Sinovac Biotech this year?

Sinovac Biotech has equity of 8.71 B USD this year.

What was the equity of Sinovac Biotech compared to the previous year?

The equity of Sinovac Biotech has increased/decreased by -2.37% decreased compared to the previous year.

What impact does a high equity have on investors of Sinovac Biotech?

A high equity is advantageous for investors of Sinovac Biotech as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Sinovac Biotech?

A low equity can be a risk for investors of Sinovac Biotech, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Sinovac Biotech affect the company?

An increase in equity of Sinovac Biotech can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Sinovac Biotech affect the company?

A reduction in equity of Sinovac Biotech can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Sinovac Biotech?

Some factors that can affect the equity of Sinovac Biotech include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Sinovac Biotech so important for investors?

The equity of Sinovac Biotech is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Sinovac Biotech take to change the equity?

To change equity, Sinovac Biotech can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Sinovac Biotech pay?

Over the past 12 months, Sinovac Biotech paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Sinovac Biotech is expected to pay a dividend of 0 USD.

What is the dividend yield of Sinovac Biotech?

The current dividend yield of Sinovac Biotech is .

When does Sinovac Biotech pay dividends?

Sinovac Biotech pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Sinovac Biotech?

Sinovac Biotech paid dividends every year for the past 0 years.

What is the dividend of Sinovac Biotech?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Sinovac Biotech located?

Sinovac Biotech is assigned to the 'Health' sector.

Wann musste ich die Aktien von Sinovac Biotech kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Sinovac Biotech from 9/21/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/21/2024.

When did Sinovac Biotech pay the last dividend?

The last dividend was paid out on 9/21/2024.

What was the dividend of Sinovac Biotech in the year 2023?

In the year 2023, Sinovac Biotech distributed 0 USD as dividends.

In which currency does Sinovac Biotech pay out the dividend?

The dividends of Sinovac Biotech are distributed in USD.